Introduction {#s1}
============

The common ancestor of the eukaryotic Apicomplexa evolved nearly 1 billion years ago ([@bib28]), and its modern descendants comprise a large phylum of intracellular parasites that are currently responsible for numerous devastating metazoan diseases, including malaria (*Plasmodium*), toxoplasmosis (*Toxoplasma*), cryptosporidiosis (*Cryptosporidium*), cyclosporiasis (*Cyclospora*), and babesiosis (*Babesia*). A key event in the early evolution of the Apicomplexa was the acquisition of a malate dehydrogenase (MDH) via lateral gene transfer from α-proteobacteria ([@bib38]; [@bib55]; [@bib88]). Following a gene duplication event roughly 700--900 Mya, one copy of this MDH evolved a novel substrate specificity to become a highly specific lactate dehydrogenase (LDH) that is now essential to the life cycle of many modern apicomplexans ([@bib65]). As a core metabolic enzyme that evolved independently of metazoan LDH, the unique apicomplexan LDH has attracted significant attention as a potential drug target ([@bib39]; [@bib62]; [@bib11]; [@bib22]). However, the molecular and evolutionary mechanisms that drove this switch in substrate specificity are currently unknown.

LDH and MDH are homologous, 2-ketoacid oxidoreductases that share both a protein fold ([@bib64]; [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}) and a common catalytic mechanism ([@bib5]; [@bib19]; [@bib42], [@bib43]; [@bib20]; [@bib76]; [Figure 1](#fig1){ref-type="fig"}). Both enzymes are found in central metabolism: MDH catalyzes the interconversion of oxaloacetate and malate in the citric acid cycle, and LDH converts pyruvate to lactate in the final step of anaerobic glycolysis. Despite their structural and catalytic similarities, modern apicomplexan LDHs and MDHs have extraordinarily strict substrate specificity. For example, *Plasmodium falciparum* (*Pf*) MDH and LDH each prefer their respective substrates by over six orders of magnitude. The biophysical basis for this extraordinary substrate preference is presently an unresolved question.10.7554/eLife.02304.003Figure 1.Schematic of M/LDH superfamily active site and catalytic mechanism.MDH reduces oxaloacetate to malate, in which the R-group is a methylene carboxylate group. LDH reduces pyruvate to lactate, in which the R-group is a methyl group. Key conserved active site residues are shown in black; substrate is shown in blue. The oxidized 2-ketoacid form of the substrate is at left; the reduced 2-hydroxy acid form is shown at right. The R-group of the substrate interacts with Arg102 in MDHs and Gln102 in canonical LDHs. Both Arg109 and position 102 are found in the mobile 'specificity loop' that closes over the active site.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.003](10.7554/eLife.02304.003)10.7554/eLife.02304.004Figure 1---figure supplement 1.Fold architecture in the LDH and MDH superfamily.At left is *Cp*MDH (blue, 2hjr), at right is *Pf*LDH (vermilion and olive, 1t2d). The Rossmann fold domain, which binds the NADH cofactor, is show as light blue in *Cp*MDH and vermilion in *Pf*LDH. The active site is found at the interface of the two domains. In *Cp*MDH, the 'opposing loop' is highlighted in yellow (see text). In *Pf*LDH, the six-residue insertion is highlighted in yellow.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.004](10.7554/eLife.02304.004)

A conspicuous structural difference between apicomplexan MDHs and LDHs is an insertion within the active site loop of the LDHs ([@bib10]; [@bib29]; [Figure 2](#fig2){ref-type="fig"}). In the LDH/MDH superfamily, closure of this loop over the active site is rate-limiting during catalysis ([@bib76]), and mutations within this loop have large effects on activity and substrate specificity ([@bib80]). For example, simply mutating Gln102 to Arg in the specificity loop of *Bacillus stearothermophilus* (*Bs*) LDH converts the enzyme into an MDH, shifting specificity from a 10^3^-fold preference for pyruvate to a 10^4^-fold preference for oxaloacetate ([@bib80]) ([Figure 1](#fig1){ref-type="fig"}, residue numbering is based on the dogfish LDH convention \[[@bib32]\]). In fact, all known MDHs have an Arg at position 102, while canonical LDHs have a Gln, and consequently residue 102 has been called the \'specificity residue\' ([@bib16]). Residue 102 is thought to contribute to substrate discrimination by balancing the substrate charge within the active site: the positively charged Arg in MDHs forms a salt bridge with the C4 carboxylate of oxaloacetate, whereas the neutral Gln in canonical LDHs packs with the C3 methyl of pyruvate ([Figure 1](#fig1){ref-type="fig"}). Yet, attempts to convert an MDH into an LDH by mutating Arg102 to Gln have met with limited success ([@bib56]; [@bib14]). In the apicomplexan LDHs, residue 102 is not a Gln but a Lys, a relatively conservative substitution compared to the MDH Arg. It is currently not understood why *Plasmodium* LDHs lack activity towards oxaloacetate, despite having a positively charged sidechain at residue 102 similar to MDHs ([@bib39]; [@bib24]; [@bib81]; [@bib9]; [@bib48]; [@bib67]).10.7554/eLife.02304.005Figure 2.Apicomplexan M/LDH active sites.Structures of *Cp*MDH (blue, 2hjr) and *Pf*LDH (vermilion, 1t2d) superposed using THESEUS. The ligands (oxalate and NAD^+^) are from 1t2d and colored white. Side chains of important residues are shown as sticks and the six-residue insert of *Pf*LDH is highlighted in yellow. Note how the *Pf*LDH Trp107f overlays Arg102 from *Cp*MDH. Residues in the insertion are labeled using numbers and letters to maintain consistency with homologous positions in the dogfish LDH.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.005](10.7554/eLife.02304.005)10.7554/eLife.02304.006Figure 2---figure supplement 1.Sequence alignment of the specificity loop from apicomplexan M/LDHs with ancestral sequences.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.006](10.7554/eLife.02304.006)10.7554/eLife.02304.007Figure 2---figure supplement 2.Alanine scanning of *Pf*LDH specificity loop.Logarithm of pyruvate k~cat~/K~M~ of *Pf*LDH and each mutant. Labels on x-axis describe the mutation tested in the WT *Pf*LDH background.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.007](10.7554/eLife.02304.007)10.7554/eLife.02304.008Figure 2---figure supplement 2---source data 1.Kinetic parameters for PfLDH alanine-scan.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.008](10.7554/eLife.02304.008)10.7554/eLife.02304.009Figure 2---figure supplement 3.Crystal structure of *Pf*LDH-W107fA mutant.(**A**) Crystal lattice of the W107fA mutant (left) compared to the WT *Pf*LDH (right). (**B**) Superposition of the WT *Pf*LDH (olive) and the W107fA mutant (vermilion). The structures are highly similar throughout, expect for the active site loop (at top), which is closed in the WT and partially disordered and open in the mutant.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.009](10.7554/eLife.02304.009)

Apicomplexan LDH evolved from the duplication of an ancestral MDH gene ([@bib38]; [@bib88]). Gene duplication is widely considered the major force that has driven the evolutionary diversity of protein functions ([@bib45]). There are three general ways duplicated genes can be fixed in a population by selection: (1) 'dosage selection', beneficial increase in dosage due to multiple copies, (2) 'subfunctionalization', specialization of previously existing functions, or (3) 'neofunctionalization', creation of a novel function through the accumulation of beneficial, gain-of-function mutations ([@bib57]). Most mutations, however, are either neutral or detrimental. A new duplicated gene typically degrades to a crippled pseudogene before it can acquire the rare beneficial mutations needed to confer a selectable function ([@bib77]; [@bib53]). Hence, classical neofunctionalization has fallen out of favor in preference for models that begin with the duplication of a multifunctional protein, such as 'specialization' and 'subfunctionalization' models. Currently the molecular and evolutionary mechanisms that create novel functions in gene duplicates are fiercely debated ([@bib35]; [@bib21]; [@bib45]; [@bib69]), and there are few clear examples of classic neofunctionalization or gain-of-function mutations ([@bib87]; [@bib8]; [@bib75]).

The apicomplexan LDH and MDH enzyme family provides an exceptional model system for investigating several long-standing questions in molecular evolution, including the mechanisms available to convergent evolution, the number of mutations required to produce a nascent function, the role of promiscuous intermediates during evolution of function, and the effects of epistasis on evolutionary irreversibility. In order to identify the biophysical and evolutionary mechanisms responsible for pyruvate specificity in apicomplexan LDHs, we have reconstructed ancestral proteins along the evolutionary trajectories leading to modern apicomplexan MDHs and LDHs ([Figure 3B](#fig3){ref-type="fig"}). We kinetically and structurally characterized the ancestral proteins together with multiple evolutionary intermediates. This work provides a clear example of neofunctionalization in protein evolution and the first crystal structures documenting the evolution of a new enzyme. We show that apicomplexan LDHs evolved as the result of few mutations of large effect via the classic neofunctionalization of a duplicated MDH gene.10.7554/eLife.02304.010Figure 3.Phylogeny of apicomplexan M/LDH superfamily.(**A**) 1844 taxa. The tree is colored according to function (LDH---vermilion; MDH---blue; HicDH---moss). The N-terminal Rossmann-fold of glucosidases and aspartate dehydrogenases (AspDHs) was used to root the phylogeny. Numbers highlight convergent events of LDH evolution from MDHs: 1--Canonical LDHs, 2--Trichomonad LDHs, and 3,4--apicomplexan LDHs. The shaded clades have highly significant supports ([@bib3]). (**B**) Apicomplexan M/LDH Clade. A close-up of the apicomplexan portion of the phylogeny in **A**, similarly colored by function. aLRT supports for each group: α-proteobacteria MDHs, 15; apicomplexan LDHs, 11; *Plasmodium* LDHs, 333; *Cryptosporidium* MDHs, 54; *Cryptosporidium* LDHs, 202. Ancestral reconstructed proteins are labeled at internal nodes (AncMDH1, AncMDH2, AncMDH3, AncLDH). The focus of the present work is the gene duplication at node 3.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.010](10.7554/eLife.02304.010)10.7554/eLife.02304.011Figure 3---figure supplement 1.Phylogeny of M/LDH superfamily.Same phylogeny as [Figure 3A](#fig3){ref-type="fig"} with select branch supports shown (aLRT supports).**DOI:** [http://dx.doi.org/10.7554/eLife.02304.011](10.7554/eLife.02304.011)10.7554/eLife.02304.012Figure 3---figure supplement 2.Phylogeny of M/LDH superfamily.Same phylogeny as [Figure 3A](#fig3){ref-type="fig"}. The tree is colored by domain of life (eubacterial---vermilion; eukaryotic---blue; archeal---magenta).**DOI:** [http://dx.doi.org/10.7554/eLife.02304.012](10.7554/eLife.02304.012)10.7554/eLife.02304.013Figure 3---figure supplement 3.Apicomplexan M/LDH Clade.Same phylogeny as [Figure 3B](#fig3){ref-type="fig"} with aLRT branch supports and clades shown in full detail.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.013](10.7554/eLife.02304.013)

Results {#s2}
=======

LDH enzymes have evolved independently at least four times {#s2-1}
----------------------------------------------------------

A maximum likelihood phylogeny of representatives of all known LDH and MDH proteins provides strong support for five distinct protein clades ([Figure 3A](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}): canonical LDHs, 'LDH-like' MDHs, mitochondrial-like MDHs, cytosolic-like MDHs, and the poorly characterized HicDHs (hydroxyisocaproate-related dehydrogenases), confirming previous phylogenetic analyses ([@bib38]; [@bib55]; [@bib88]; [@bib54]).

The HicDH clade are close sequence homologs of a known hydroxyisocaproate dehydrogenase. They all possess a residue other than a Gln or an Arg at the 'specificity' position 102, as well as insertions of varying lengths within the catalytic loop between residues 102 and 109. Despite these alterations within the catalytic loop, all other catalytic residues (Arg109, Asp168, Arg171, and His195) are conserved. Only one taxon within the HicDH clade has been functionally characterized, DHL2_LACCO, which is a specific hydroxyisocaproate dehydrogenase ([@bib33]). These observations suggest that the clade features dehydrogenases with altered substrate specificity.

Except for the HicDHs, which are exclusively eubacterial, both eukaryotic and eubacterial enzymes are found in all major clades ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}). The 'LDH-like' MDH clade additionally contains archaeal dehydrogenases, which are basal and group to the exclusion of the bacterial MDHs.

Intriguingly, three different groups of LDH proteins cluster with high confidence outside of the canonical LDH clade. A set of trichomonad LDHs found in the cytosolic-like MDH clade are thought to have evolved from a recent gene duplication of an MDH ([@bib84]). The Trichomonads appear to lack a canonical LDH. A prominent eukaryotic group of LDH and MDH proteins from the Apicomplexa nests deep within the bacterial 'LDH-like' MDHs, sister to many Rickettsiales sequences, signifying a horizontal gene transfer event from α-proteobacteria to the eukaryotic Apicomplexa. We find no evidence that the Apicomplexa have canonical LDH or conventional eukaryotic-type MDH (either cytosolic- or mitochondrial-like MDHs), despite searching in many available complete apicomplexan genomes (multiple Eimeria, Neospora, Toxoplasma, Plasmodium, and Cryptosporidium species) ([@bib44]; [@bib36]; [@bib4]). In the Apicomplexa, LDH activity has apparently evolved independently twice ([Figure 3B](#fig3){ref-type="fig"}, [Figure 3---figure supplement 3](#fig3s3){ref-type="fig"}), once in a lineage leading to *Plasmodium*-related species and once in *Cryptosporidium*. The apicomplexan portion of the LDH/MDH gene phylogeny is consistent with recent apicomplexan species phylogenies constructed from concatenated protein sequences ([@bib71]).

We rooted the MDH/LDH phylogeny using the Rossmann fold domain of the distantly related α/β-glucosidases and aspartate dehydrogenases as outgroups. The ML root position apparently splits the tree into two large groups: one which contains the cytosolic- and mitochondrial-like MDHs, which are largely dimeric, and another which contains the canonical LDHs, 'LDH-like' MDHs, and HicDHs, which are primarily tetrameric ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). While the ML root position is robust to variation in taxon coverage, the exact location is poorly supported. Nevertheless, there is strong support for a root position within the central MDH section of the tree and outside of the five identified clades, including the canonical LDH clade (confidence level \>0.99985 according to the aLRT), indicating that the canonical LDHs evolved from an ancestral MDH. The global rooting and the location of the three separate LDH groups, deep within MDH clades, indicate that LDH enzymes have evolved convergently from MDHs at least four times in the superfamily.

An insertion in the catalytic loop of apicomplexan LDHs {#s2-2}
-------------------------------------------------------

In the present work, our focus is on the convergent evolution of the unusual apicomplexan LDHs. With the α-proteobacterial 'LDH-like' MDHs as the closest outgroup, the apicomplexan enzymes are split into two main groups: LDHs belonging to *Toxoplasma*, *Plasmodium,* and related protists, and MDHs belonging to *Plasmodium* and *Cryptosporidium*. Apart from their atypical phylogenetic position, the apicomplexan MDHs appear as typical α-proteobacterial 'LDH-like' MDHs, containing all the key catalytic residues including Arg102. The *Cryptosporidium* LDHs are an exception, being nested within the apicomplexan MDH clade partitioned from the rest of the apicomplexan LDHs. *Cryptosporidium* LDHs have a Gly at position 102 and are thought to be a product of an independent, convergent duplication event ([@bib54]).

In contrast, the large apicomplexan LDH clade is demarcated by a unique, conserved five-residue insertion in the active site loop. While the apicomplexan LDH and MDH proteins are moderately divergent, with about 45% sequence identity, the differences are largely confined to exterior residues removed from the active sites. One important difference is that the apicomplexan LDHs have Lys102 for the 'specificity residue', rather than a Gln as found in the canonical LDHs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). Apicomplexan proteins frequently contain numerous insertions relative to proteins from other species ([@bib34]; [@bib50]), a characteristic thought to result from various factors, including high AT genome content, DNA strand slippage, double strand break repair, high recombination rates, and selection pressure for parasite antigenic variation. Except for Met106, the amino acid and coding sequence immediately flanking the apicomplexan LDH loop insertion is largely conserved with α-proteobacterial MDHs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}). It is therefore likely that a mutation 'expanded' the Met106 codon to code for six residues, resulting in the observed five-residue insertion and the Met106Lys mutation. Henceforth we will refer to this expansion mutation as the 'six-residue loop insertion'.

Trp107f is the modern apicomplexan LDH specificity residue {#s2-3}
----------------------------------------------------------

In the modern apicomplexan enzymes, the six-residue insertion in the LDH specificity loop (positions 99--112) induces two significant structural changes relative to MDH ([Figure 2](#fig2){ref-type="fig"}). First, LDH residue Lys102 is excluded from of the active site, unlike the corresponding Arg102 in MDH, which is enclosed within the active site and participates in functionally important interactions with the substrate. Second, LDH Trp107f, which is part of the novel insertion, occupies the same space as Arg102 in MDH (by convention, residues in the insertion are labeled using numbers and letters to maintain consistency with homologous positions in the dogfish LDH, [Figure 2](#fig2){ref-type="fig"}).

The only prominent structural difference between the active sites of the LDH and MDH proteins is the replacement of MDH Arg102 with LDH Trp107f. Trp107f is positioned where it could presumably interact with the distinguishing C3 methyl of the pyruvate substrate, while MDH Arg102 interacts with the C4 carboxylate of oxaloacetate ([@bib16]). As a bulky, hydrophobic residue, Trp107f could recognize pyruvate in preference to oxaloacetate by two mechanisms: a hydrophobic interaction with the pyruvate C3 methyl vs the negatively charged oxaloacetate methylene carboxylate and steric occlusion of the methylene carboxylate of oxaloacetate. Furthermore, Trp107f is conserved in all apicomplexan LDHs ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), suggesting negative selection and functional importance. We therefore hypothesized that Trp107f plays an important role in pyruvate recognition.

We tested the functional importance of residues in the specificity loop in *Pf*LDH with an 'alanine scan' by individually mutating each residue in positions 101--108 to an alanine ([Figure 2---figure supplement 2](#fig2s2){ref-type="fig"}, note Ala103 was mutated to a serine). We assessed the activity of the mutants using k~cat~/K~m~, a measure of enzymatic specificity and catalytic efficiency, as determined from steady state kinetic assays. Mutating Trp107f to Ala reduced pyruvate activity by five orders of magnitude, whereas mutations at all other positions had effects less than a single order of magnitude, including the canonical specificity residue at position 102. The Trp107fAla mutation affects both k~cat~ (1500-fold decrease) and K~m~ (50-fold increase).

To assess the effects of Trp107fAla mutation on the specificity loop conformation, we solved the crystal structure of *Pf*LDH-W107fA (1.1 Å ) in the presence of oxamate and NADH. The protein crystallizes in the same space group as the wild-type *Pf*LDH, with nearly identical cell dimensions ([Figure 2---figure supplement 3A](#fig2s3){ref-type="fig"}). In the W107fA mutant, the specificity loop is disordered between residues Thr101 and Arg109, as is often seen in structures in which the loop is in the open conformation. In the mutant, residues 112--115 are in a linear α-helical conformation, in contrast to the wild-type *Pf*LDH closed state which has a very prominent 60° kink in the α-helix at Pro114. Thus, the only significant difference between the wild-type and mutant structures is that the *Pf*LDH-W107fA specificity loop is found in the open conformation, consistent with weaker binding of substrate ([Figure 2---figure supplement 3B](#fig2s3){ref-type="fig"}). These results indicate that Trp107f is necessary for pyruvate activity in apicomplexan LDHs, and that it has become the new 'specificity residue' despite the fact that Trp107f does not align in sequence with the canonical specificity residue at position 102 ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}).

The loop insert fails to swap specificity in modern LDH and MDH {#s2-4}
---------------------------------------------------------------

During evolution, the six-residue insertion displaced the canonical specificity residue at position 102 and apparently switched substrate preference in apicomplexan LDHs. If this insertion is sufficient for pyruvate recognition, then adding the insertion to a modern apicomplexan MDH should convert the enzyme to an LDH. To test this hypothesis, we incorporated the six-residue insertion from *Pf*LDH into the catalytic loop of *Pf*MDH (*Pf*MDH-INS) and the *Cryptosporidium parvum* (*Cp*) MDH (*Cp*MDH-INS). The chimeric proteins showed a \>100-fold reduction in oxaloacetate activity with no significant gain in pyruvate activity ([Figure 4](#fig4){ref-type="fig"}). Like other MDHs, the apicomplexan MDHs have an Arg at position 102 that is important for oxaloacetate recognition; in the modern apicomplexan LDHs position 102 is a Lys. The Arg102Lys mutation may be necessary to eliminate oxaloacetate activity and increase pyruvate activity. Therefore, we also mutated Arg102 to Lys in the *Pf*MDH chimera (*Pf*MDH-R102K-INS). However, this mutation reduced activity towards oxaloacetate by another 100-fold, with no increase in pyruvate activity ([Figure 4](#fig4){ref-type="fig"}).10.7554/eLife.02304.014Figure 4.Specificity switching in apicomplexan M/LDHs.Blue horizontal bars (left) quantify activity towards oxaloacetate; vermilion horizontal bars (right) quantify activity towards pyruvate. Activity is measured as log~10~(k~cat~/K~M~ ), where k~cat~/K~M~ is in units of s^-1^M^−1^. Error bars are shown as small black brackets and represent 1 SD of the mean from triplicate measurements. INS refers to the presence of the six-residue insertion from *Pf*LDH, DEL refers to the removal of the six-residue insertion. Relative specificity (RS) is the ratio of k~cat~/K~M~ for pyruvate vs oxaloacetate, with positive log~10~(RS) representing a preference for pyruvate and negative log~10~(RS) representing a preference for oxaloacetate. All logarithms are base 10.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.014](10.7554/eLife.02304.014)10.7554/eLife.02304.015Figure 4---source data 1.Kinetic parameters for modern constructs.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.015](10.7554/eLife.02304.015)

Alternatively, it may be possible to revert a modern apicomplexan LDH to MDH-like specificity by deleting its six-residue loop insertion. To test this hypothesis we removed the insertion from *Pf*LDH and from the *Toxoplasma gondii* (*Tg*) LDH2 (constructs *Pf*LDH-DEL and *Tg*LDH2-DEL). However, deleting the insertion from the modern LDHs abolishes pyruvate activity with no significant gain of oxaloacetate activity ([Figure 4](#fig4){ref-type="fig"}). Both of these deletion mutants retain a Lys at position 102, but a specific MDH likely requires an Arg at position 102. Mutating Lys102 to Arg in *Pf*LDH-DEL results in a two order-of-magnitude gain in oxaloacetate activity ([Figure 4](#fig4){ref-type="fig"}). However, this mutant fails to recapitulate the level of oxaloacetate activity seen in modern apicomplexan MDHs. In the modern enzymes, substrate specificity cannot be switched with mutations involving the loop insert and position 102, indicating that additional residues govern substrate preference.

The ancestral MDH and LDH enzymes are specific and highly active {#s2-5}
----------------------------------------------------------------

The apicomplexan LDH and MDH phylogeny strongly suggests that after (or coincident with) the crucial gene duplication event, the nascent LDH branch gained pyruvate activity due to the six-residue insertion in the specificity loop. This presents a conundrum, as our mutation trials in the modern enzymes failed to recapitulate the historical swap in specificity. However, the modern apicomplexan LDH and MDH enzymes differ by over 200 residues in addition to the loop insert and Arg102Lys, differences that have accumulated in the descendants of the ancestral MDH and LDH. Any of these differences may detrimentally affect the ability to switch substrate specificity with the insertion in the modern enzymes. We therefore reasoned that the ancestral background may be necessary for swapping specificity with the loop insertion. To test this, we reconstructed and characterized four key ancestral enzymes: AncMDH1, the ancestral protein that was transferred from α-proteobacteria to the archaic Apicomplexa, AncMDH2, the last common ancestor of all apicomplexan MDHs and LDHs, found at the critical duplication event, AncMDH3, the last common ancestor of all modern apicomplexan MDHs, and AncLDH, the last common ancestor of modern apicomplexan LDHs ([Figure 3B](#fig3){ref-type="fig"}).

All four ancestral proteins are highly active in steady state kinetic assays, with substrate preferences and catalytic efficiencies that are similar to their modern apicomplexan descendants ([Figure 5](#fig5){ref-type="fig"}), despite sharing only 49--71% sequence identity with the modern apicomplexan proteins ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). AncMDH1, AncMDH2, and AncMDH3 are highly specific MDHs with negligible pyruvate activity, having even greater activity towards oxaloacetate than modern *Plasmodium* and *Cryptosporidium* MDHs ([Figure 5](#fig5){ref-type="fig"}). AncLDH is a highly active and specific LDH, with very low activity towards oxaloacetate ([Figure 5](#fig5){ref-type="fig"}).10.7554/eLife.02304.016Figure 5.Evolution of novel LDHs in Apicomplexa.The activities of ancestral and modern apicomplexan M/LDHs are plotted on the corresponding nodes of the protein phylogeny. Nodes are numbered as in [Figure 3B](#fig3){ref-type="fig"}. The y-axis of the bar graphs is log(k~cat~/K~M~), with oxaloacetate in blue and pyruvate in vermilion. *Rb*MDH is a representative α-proteobacterial MDH from *Rickettsia bellii*. *T. gondii* has two LDH proteins (TgLDH1 and TgLDH2), each expressed at different stages of the life cycle ([@bib24]).**DOI:** [http://dx.doi.org/10.7554/eLife.02304.016](10.7554/eLife.02304.016)10.7554/eLife.02304.017Figure 5---source data 1.Kinetic parameters for ancestral/modern phylogeny.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.017](10.7554/eLife.02304.017)10.7554/eLife.02304.018Figure 5---figure supplement 1.Sequence identity of ancestral and modern proteins.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.018](10.7554/eLife.02304.018)

The loop insert successfully swaps specificity in both ancestral LDH and MDH {#s2-6}
----------------------------------------------------------------------------

AncLDH differs from AncMDH2 by 66 residues, including the six-residue insertion and Arg102Lys. We investigated the evolutionary trajectory from AncMDH2 to AncLDH by characterizing three different mutations in the AncMDH2 background: the addition of AncLDH\'s six-residue insertion to the AncMDH2 specificity loop, Arg102Lys, which assesses the effect of changing the canonical specificity residue, and the remaining 59 residues that separate AncLDH from AncMDH2, simultaneously changed to their AncLDH identities.

Incorporating the loop insertion into AncMDH2 confers significant pyruvate activity with minimal effect on oxaloacetate activity, resulting in a highly active, bifunctional enzyme (AncMDH2-INS, [Figure 6](#fig6){ref-type="fig"}). In contrast, the Arg102Lys mutation in the AncMDH2 background (AncMDH2-R102K, [Figure 6](#fig6){ref-type="fig"}) reduces oxaloacetate activity by more than a 100-fold, with no increase in pyruvate activity. The 59 mutations in the AncMDH2 background have a minimal effect on the activity towards both substrates (AncMDH2-59Mut, [Figure 6](#fig6){ref-type="fig"}). Note that the AncMDH2-59Mut construct is equivalent to a modified AncLDH construct with the Lys102Arg mutation and the insertion deleted from the loop. Therefore, only two changes---Lys102Arg and the loop deletion---are sufficient to convert the AncLDH construct to a highly active and specific MDH.10.7554/eLife.02304.019Figure 6.Specificity switching in ancestral MDH2.INS refers to the reconstructed six-residue insertion from AncLDH. 59Mut is described in the text. Relative specificity (RS) is described in legend of [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.019](10.7554/eLife.02304.019)10.7554/eLife.02304.020Figure 6---source data 1.Kinetic parameters for ancestral specificity switch mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.020](10.7554/eLife.02304.020)10.7554/eLife.02304.021Figure 6---source data 2.Source data for figure supplement 7. Kinetic parameters for alternative ancestral proteins.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.021](10.7554/eLife.02304.021)10.7554/eLife.02304.022Figure 6---figure supplement 1.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.022](10.7554/eLife.02304.022)10.7554/eLife.02304.023Figure 6---figure supplement 2.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.023](10.7554/eLife.02304.023)10.7554/eLife.02304.024Figure 6---figure supplement 3.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.024](10.7554/eLife.02304.024)10.7554/eLife.02304.025Figure 6---figure supplement 4.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.025](10.7554/eLife.02304.025)10.7554/eLife.02304.026Figure 6---figure supplement 5.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.026](10.7554/eLife.02304.026)10.7554/eLife.02304.027Figure 6---figure supplement 6.Histogram of ancestral reconstructions.Reconstructed residues binned according to posterior probability (PP) of the predicted residue.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.027](10.7554/eLife.02304.027)10.7554/eLife.02304.028Figure 6---figure supplement 7.Alternative ancestral enzymes.INS refers to the reconstructed six amino acid insertion from AncLDH\*. 58Mut refers to remaining residue differences between AncMDH\* and AncLDH\* that are not R102K or INS. Relative specificity (RS) is described in legend of [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.028](10.7554/eLife.02304.028)

Combinations of these mutations confirm that the insertion is primarily responsible for the evolution of pyruvate activity. Adding the 59 mutations to AncMDH2-INS (resulting in a construct that differs from AncLDH by only one residue) has little additional effect (AncMDH2-INS-59Mut, [Figure 6](#fig6){ref-type="fig"}). Surprisingly, the combination of Arg102Lys and the 59 mutations, a construct that differs from AncLDH by just the six-residue insertion, yields a crippled MDH enzyme with 1000-fold less oxaloacetate activity than AncMDH2 (AncMDH2-R102K-59Mut, [Figure 6](#fig6){ref-type="fig"}). However, the combination of Arg102Lys and the loop insertion in the AncMDH2 background is sufficient to confer pyruvate activity and specificity comparable to AncLDH (AncMDH2-INS-R102K, [Figure 6](#fig6){ref-type="fig"}).

Ancestral kinetics are robust to reconstruction uncertainty {#s2-7}
-----------------------------------------------------------

Ancestral sequence reconstruction is a difficult statistical problem that strongly relies on evolutionary assumptions, which may be unrealistic, and on available sequence data, which is inherently incomplete. The likelihood and Bayesian ancestral reconstruction methodology that we use produces the most probable ancestral sequence given certain evolutionary model assumptions, along with a posterior probability for alternative amino acids at each position ([Figure 6---figure supplements 1--6](#fig6s1 fig6s2 fig6s3 fig6s4 fig6s5 fig6s6){ref-type="fig"}). Ambiguous residues are generally associated with positions of low conservation and presumably less functional importance. The reconstructed AncMDH2 and AncLDH sequences have 31 and 48 ambiguous positions, respectively, all of which are located outside of the 'first active site shell' (defined as within 6 Å of the substrate). In order to verify that these sequence ambiguities do not affect our kinetic results, alternative ancestral sequences were reconstructed and assayed. We tested the robustness of our ancestral proteins by constructing alternative ancestors based on perturbed sequence data, evolutionary assumptions, and phylogenetic methodology. Both phylogenies give very similar relationships, and [Figure 2B](#fig2){ref-type="fig"} summarizes both equally well. The alternative AncMDH2 (AncMDH2\*) differs from AncMDH2 by 27 residues; the alternative AncLDH (AncLDH\*) differs from AncLDH by 19 residues.

The alternative ancestral reconstructions behave very similar to the prior reconstructions. AncMDH2\* is a strict MDH, and AncLDH\* is a strict LDH ([Figure 6](#fig6){ref-type="fig"}, [Figure 6---figure supplement 7](#fig6s7){ref-type="fig"}). Addition of the six-residue insertion from AncLDH\* to AncMDH2\* confers pyruvate specificity without adversely affecting oxaloacetate activity (AncMDH2\*-INS, [Figure 6---figure supplement 7](#fig6s7){ref-type="fig"}). In the AncMDH2\* background, mutating Arg102 to Lys together with the 58 mutations from AncLDH\* yields a poor enzyme with little pyruvate activity (AncMDH2\*-R102K-58Mut). The kinetic behavior of these AncMDH2\* constructs closely matches those seen with the corresponding AncMDH2 constructs (AncMDH2, AncMDH2-INS, and AncMDH2-R102K-59Mut, [Figure 6](#fig6){ref-type="fig"}).

Crystal structures of ancestral MDH, LDH, and an evolutionary intermediate {#s2-8}
--------------------------------------------------------------------------

In order to understand the structural changes during evolution that shifted the enzymatic substrate specificity of the apicomplexan dehydrogenases, we determined the high-resolution crystal structures of three ancestral proteins bracketing the key duplication event: AncMDH2, AncLDH\*, and AncMDH2-INS. Each protein was crystallized with multiple substrates or ligands (lactate, malate, and oxamate inhibitor) and with NADH (resolution ranging from 1.35 Å to 2.05 Å). Unfortunately, in all crystals with malate, the malate spontaneously converted to pyruvate and/or lactate via redox reactions and decarboxylation. In the crystals constructed with AncMDH2 and lactate, a phosphate was seen in the active site rather than lactate. In the following, therefore, the descriptions of the models are primarily based on enzymes crystallized with oxamate inhibitor or lactate, which are highly similar. All three ancestral proteins adopt the same overall fold and conformation as the modern, descendant enzymes. In particular, the ancestral active sites and specificity loops are highly similar to their modern counterparts.

Ancestral malate dehydrogenase: AncMDH2 {#s2-9}
---------------------------------------

The AncMDH2 structure superposes closely with the modern *Cp*MDH structure ([@bib74]) (∼0.6 Å RMSD for the loop-closed states), although differing at ∼119 residue positions (62% sequence identity, [Figure 7A](#fig7){ref-type="fig"}). In the modern and ancestral MDHs, all residues within the first shell of the active sites (within 6 Å of the substrate) are identical, and the active site conformations are correspondingly highly similar ([Figure 7B](#fig7){ref-type="fig"}). The first shell active site residues comprise Arg102, Arg109, Leu112, Asn140, Leu167, Asp168, Arg171, His195, Met199, Gly236, Gly237, Ile239, Val240, Ser245, Ala246, and Pro250.10.7554/eLife.02304.029Figure 7.Ancestral and modern dehydrogenase structures.(**A**) Superposition of *Cp*MDH and AncMDH2. Superposition of AncMDH2 structure (blue, 4plw, chain C) and *Cp*MDH (aquamarine, 2hjr, chain A). Ligands from AncMDH2 are shown in gray; ligands from *Cp*MDH are in white. (**B**) Active site detail of *Cp* MDH and AncMDH2. Side chains of catalytic residues highlighted as sticks. (**C**) Superposition of apicomplexan LDHs and AncLDH\*. Superposition of AncLDH\* structure (vermilion, 4plg, chain A) and four apicomplexan LDHs (deep olive, *Pf*LDH, 1t2d, chain A, *Plasmodium berghei* (*Pb*) LDH, 1oc4, chain B, *Tg*LDH1, 1pzh, chain A, *Tg*LDH2, 1sow, chain B). Ligands from AncLDH\* are shown in gray, ligands from apicomplexan LDHs are in white. The 'opposing loop' and residues 236 and 246 (discussed in text) are highlighted in cyan. (**D**) Active site detail of apicomplexan LDHs and AncLDH\*. Side chains of catalytic residues highlighted as sticks. (**E**) Superposition of ancestral dehydrogenases. Superposition of AncMDH2 (blue, 4plw, chain C), AncLDH\* (vermilion, 4plg, chain A), and AncMDH2-INS (magenta, 4ply, chain F and 4plv, chain B). Ligands are shown in gray. (**F**) Active site detail of ancestral dehydrogenases. Side chains of catalytic residues highlighted as sticks.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.029](10.7554/eLife.02304.029)10.7554/eLife.02304.030Figure 7---figure supplement 1.Crystallographic statistics table for AncLDH\*, AncMDH2, AncMDH2-INS, and *Pf*LDH-W107fA structures.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.030](10.7554/eLife.02304.030)

Compared to the modern MDH, only slight differences are seen in the substrate loop backbone and the positioning of the Arg102 and Arg109 sidechains, which are the only residues from the specificity loop that directly interact with the substrate. However, these modest conformational differences are largely within coordinate error, as the loop residues have some of the highest B-factors in the structures. Furthermore, AncMDH2 was crystallized with lactate/oxamate and NADH, while *Cp*MDH was crystallized with citrate and ADPR (an NADH analog lacking the nicotinamide ring). Citrate is roughly three times larger than lactate and has likely affected the position of substrate loop in the *Cp*MDH structure.

### Ancestral lactate dehydrogenase: AncLDH\* {#s2-9-1}

The ancestral AncLDH\* and modern apicomplexan LDH structures are likewise highly similar ([@bib81]; [@bib11]; [@bib48]) (RMSD ∼0.8 Å for the loop-closed states, [Figure 7C](#fig7){ref-type="fig"}), while sharing only 63--71% sequence identity. The first shell active site residues are identical in the AncLDH\* and modern *Toxoplasma* LDHs, comprising the same residues as the apicomplexan MDH active site with the sole exception of position 102, which is replaced by Trp107f in the LDHs. The modern *Plasmodium* LDHs have two different residues in the active site first shell: Pro246 and Ala236, rather than Ala246 and Gly236 as found in *Tg*LDH1, *Tg*LDH2, and AncLDH\*. The conformations of the ancestral and modern active sites are nearly indistinguishable, with only small differences in the specificity loop conformation ([Figure 7D](#fig7){ref-type="fig"}).

In both the ancestral and modern LDH structures, Trp107f and Arg109 are the only residues from the specificity loop that interact with the substrate. As in the modern LDH structures, ancestral Lys102 does not interact with the substrate but points away from the active site into solution. In contrast, Trp107f is buried within the active site, with the edge of the indole ring interacting with the pyruvate C3 methyl, which is the very chemical moiety that distinguishes pyruvate from oxaloacetate.

The largest differences between the modern and ancestral proteins are confined to two regions: a small shift of the entire C-terminal helix, and a loop opposite the active site specificity loop (residues 242--244, hereafter called the 'opposing loop'). The modern *Plasmodium* LDHs have a two-residue deletion within this opposing loop (highlighted in cyan in [Figure 7C](#fig7){ref-type="fig"}), while the opposing loop is shared with AncLDH\* and the *Toxoplasma* LDHs. The ancestral LDHs also share very modest oxaloacetate activity with the modern *Toxoplasma* LDHs, while the *Plasmodium* LDHs lack oxaloacetate activity ([Figure 5](#fig5){ref-type="fig"}). This correlation indicates the opposing loop deletion (and perhaps Ala236 and Pro246) may be responsible for the unusually strict substrate specificity of the modern *Plasmodium* LDHs.

Ancestral malate dehydrogenase with loop insertion: AncMDH2-INS {#s2-10}
---------------------------------------------------------------

We also crystallized AncMDH2-INS, a bifunctional AncMDH2 construct with the six-residue specificity loop insertion. This AncMDH2-INS construct represents a possible intermediate along the evolutionary trajectory between the MDH duplication event and the ancestral apicomplexan LDH. AncMDH2-INS was successfully co-crystallized with both oxamate/NADH and lactate/NADH. In the loop-closed state, the specificity loop adopts an LDH-like confirmation with Trp107f occupying the specificity position and Arg102 oriented into solution, similar to how Lys102 is positioned in the modern and ancestral LDH structures ([Figure 7F](#fig7){ref-type="fig"}). The lactate and oxamate structures are highly similar (RMSD ∼0.2 Å), and the active site architectures are nearly indistinguishable.

The three ancestral proteins, AncMDH2, AncLDH\*, and AncMDH2-INS, are all highly similar (RMSD 1.20 Å) with the main structural differences found in the conformation of the specificity loop ([Figure 7E](#fig7){ref-type="fig"}, RMSD ∼0.9 Å excluding residues in the specificity loop). Otherwise the first shell active site residues are identical between AncMDH2-INS and AncLDH\*, and the conformations of the active sites are correspondingly similar ([Figure 7F](#fig7){ref-type="fig"}).

Convergent pathways available to the ancestral MDH {#s2-11}
--------------------------------------------------

Given the known importance of position 102, the 'specificity residue', in substrate recognition, we wondered whether different residues at position 102 could confer pyruvate activity. Position 102 in fact differs in the four convergent LDH families: Gln in canonical LDHs ([@bib80]), Lys in the apicomplexan LDHs, Gly in *Cryptosporidium* LDHs ([@bib54]), and Leu in trichomonad LDHs ([@bib84]). Could the ancestral apicomplexan MDH have evolved pyruvate specificity by any of these alternative routes? To answer this question, we evaluated the potential of these different amino acids at the 102 position to confer pyruvate specificity in the AncMDH2 background. Each mutation increases pyruvate activity, but none result in a highly specific LDH. The canonical mutation (Arg102Gln) results in the largest gain in pyruvate activity (2800-fold) and the smallest loss of oxaloacetate activity (2500-fold) ([Figure 8](#fig8){ref-type="fig"}). Additionally, we tested whether the full six amino acid insertion was required to confer pyruvate specificity in AncMDH2 or if simply mutating Arg102 to Trp was sufficient. The Arg102Trp mutation all but abolishes activity towards both substrates, indicating that the loop insertion was necessary to switch the specificity residue ([Figure 8](#fig8){ref-type="fig"}).10.7554/eLife.02304.031Figure 8.Alternative LDH mutations in AncMDH2.Relative specificity (RS) is described in legend of [Figure 4](#fig4){ref-type="fig"}.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.031](10.7554/eLife.02304.031)10.7554/eLife.02304.032Figure 8---source data 1.Kinetic parameters for specificity residue mutants.**DOI:** [http://dx.doi.org/10.7554/eLife.02304.032](10.7554/eLife.02304.032)

Discussion {#s3}
==========

An alternate mechanism of specificity in the convergent apicomplexan LDH {#s3-1}
------------------------------------------------------------------------

Substrate recognition in the canonical MDHs and LDHs is thought to be determined by a 'specificity residue' in the active site loop at position 102. All known MDHs have Arg at position 102, while canonical LDHs have Gln ([@bib16]). In the classic explanation of the molecular mechanism of substrate specificity, residue 102 discriminates between pyruvate and oxaloacetate primarily via charge conservation ([@bib80]). In MDHs, the positively charged Arg interacts with and balances the negatively charged carboxylate of oxaloacetate. If pyruvate were to bind in the active site, loop closure would result in a buried and unbalanced positive charge, which is unfavorable. In canonical LDHs, the neutral Gln interacts with the neutral pyruvate methyl group. Oxaloacetate binding would similarly result in the unfavorable burial of an unbalanced negative charge.

In the apicomplexan LDHs, evolution has converged on pyruvate specificity using an alternative molecular mechanism. Residue 102 is not a Gln but a positively charged Lys, similar to Arg102 of MDHs, leading many researchers to wonder why apicomplexan LDHs lack activity towards oxaloacetate ([@bib39]; [@bib24]; [@bib81]; [@bib9]; [@bib48]; [@bib67]). However, during the evolution of the apicomplexan LDH from the ancestral MDH, the six-residue insertion in the active site loop shifted both the position and identity of the 'specificity residue' from Arg102 to Trp107f. Due to the insertion, residue 102 no longer interacts with the substrate and is extruded from the active site. In contrast, the hydrophobic Trp107f packs against the C3 methyl of the pyruvate substrate. Similar to the canonical LDH, oxaloacetate binding would result in an unbalanced and buried negative charge. As a large bulky residue, Trp107f can also occlude binding of the larger oxaloacetate, in which a methylene carboxylate replaces the pyruvate methyl.

However, as discussed in detail below, this simplistic explanation is complicated by long-range epistatic interactions. When the six-residue insertion is introduced into the modern apicomplexan MDH, specificity is not switched; both specificity and activity are lost. Similarly, removal of the insertion from the modern apicomplexan LDHs fails to swap specificity and kills the enzymes. Therefore, while Trp107f is necessary for substrate specificity in the apicomplexan enzymes (as indicated by the alanine scan mutations), it is insufficient to confer specificity.

The bifunctionality of AncMDH2-INS and AncMDH2-INS-59Mut also presents a conundrum. Why do these constructs have high activity towards both pyruvate and oxaloacetate substrates? The crystal structure of AncMDH2-INS offers few clues, since the loop insertion, including Trp107f, adopts the same conformation as seen in AncLDH and the modern apicomplexan enzymes. Both the AncMDH2-INS and AncMDH2-INS-59Mut constructs have an Arg at position 102, like the MDHs. In fact, the bifunctional AncMDH2-INS-59Mut enzyme differs from the strict AncLDH by only a R102K mutation, suggesting that Arg102 is responsible for the oxaloacetate activity of AncMDH2-INS and AncMDH2-INS-59Mut. We speculate that perhaps the enzymes change conformation depending upon the substrate. When using pyruvate, these bifunctional enzymes may adopt an LDH-like conformation in which Trp107f interacts with the substrate (as seen in the crystal structure). On the other hand, when presented with oxaloacetate, perhaps Trp107f flips out of the active site, and Arg102 flips in to interact with substrate in a manner similar to the canonical MDHs. We are currently testing this hypothesis.

Apicomplexan LDH evolved by classical neofunctionalization {#s3-2}
----------------------------------------------------------

Our data show that apicomplexan LDHs evolved from a horizontally transferred proteobacterial MDH by a classic neofunctionalization mechanism of gene duplication. Because debasement to a pseudogene is much more likely to occur prior to the evolution of a novel function, neofunctionalization has fallen out of favor as a mechanism for the evolution of novel functions. A variety of alternative specialization models have been proposed that feature a reduced risk of non-functionalization. Though differing in details, all specialization models feature a promiscuous common ancestor of the duplicated proteins.

The reconstructed AncMDH2, which represents the last common ancestor of the apicomplexan MDH and LDHs, is a highly active and specific MDH, preferring oxaloacetate over pyruvate by seven orders of magnitude ([Figure 6](#fig6){ref-type="fig"}). The activity of AncMDH2 towards pyruvate is barely detectable, requiring a high enzyme concentration to quantify. AncMDH2\'s k~cat~ for pyruvate is 0.07 s^−1^, with a K~m~ of 20 mM, while the physiological concentration of pyruvate is estimated to be about three orders-of-magnitude lower (e.g., ∼50 μM in human erythrocytes \[[@bib37]\], the *Plasmodium* host during its blood stage). Based on these kinetic parameters, each AncMDH2 reduces one pyruvate molecule per hour. While the enzyme can be forced to reduce pyruvate in vitro, this negligible activity is unlikely to have been subjected to selection in vivo. Therefore, the various specialization hypotheses, which require a promiscuous ancestor, are poor models for apicomplexan LDH evolution. Activity towards pyruvate increased by over seven orders of magnitude on the evolutionary lineage between AncMDH2 and AncLDH, indicating neofunctionalization.

A highly active, promiscuous intermediate {#s3-3}
-----------------------------------------

One of the most favored specialization models is 'escape from adaptive conflict' (EAC) ([@bib26]). EAC holds that functional specialization is driven by an inability to simultaneously optimize multiple functions on a single protein scaffold. Gene duplication relieves this constraint and allows for the independent optimization of conflicting functions. Although the apicomplexan AncMDH2 is highly specific, promiscuous intermediates did play a role in the functional transition between AncMDH2 and AncLDH. AncMDH2-INS and AncMDH2-INS-59Mut have high levels of MDH and LDH activity in a single protein scaffold ([Figure 6](#fig6){ref-type="fig"}). Both the presence of bifunctional intermediates and the high specificity of AncMDH2 conflict with fundamental predictions of the EAC specialization model.

Convergent evolution of apicomplexan LDH involved long-range epistasis {#s3-4}
----------------------------------------------------------------------

The evolution of apicomplexan LDHs involved strong epistasis that has profoundly influenced the convergent evolution of pyruvate activity. Epistasis refers to interactions between residues that potentiate the effects of a mutation depending on the presence or absence of other residues ([@bib41]). Epistasis can constrain the order of mutations and the pathways accessible to evolution, and hence it is of great importance in understanding the evolution of novel functions. In the apicomplexan dehydrogenases, the evolutionary mutations that switched specificity from oxaloacetate to pyruvate (the six-residue insertion and Arg102Lys) are insufficient to confer pyruvate activity in modern apicomplexan MDHs (*Pf*MDH-R102K, *Pf*MDH-INS, *Cp*MDH-INS, *Pf*MDH-R102K-INS, [Figure 4](#fig4){ref-type="fig"}). However, these mutations are sufficient to confer pyruvate function and specificity in the AncMDH2 background (AncMDH2-INS, AncMDH2-INS-R102K, [Figure 6](#fig6){ref-type="fig"}). Similarly, removal of the insert from the modern LDHs (*Pf*LDH-DEL and *Tg*LDH2-DEL, [Figure 4](#fig4){ref-type="fig"}) kills the enzymes, while removal of the insert from the ancestral LDH (AncMDH2-R102K-59Mut, [Figure 6](#fig6){ref-type="fig"}) results in a weak MDH. The different effects of these mutations, depending upon the sequence of the rest of the protein, provide direct evidence of epistatic interactions.

Why do these historical mutations 'work' in the ancestral enzymes, but not in the modern ones? Epistatic interactions are often mediated by direct physical contact. For example, the active site of the ancestral MDH could have certain residues that the modern MDH lacks, residues that interact with the insertion and allow it to preferentially bind pyruvate. However, the active sites of the ancestral and modern MDHs are identical in sequence and virtually indistinguishable in structure ([Figure 7B](#fig7){ref-type="fig"}), as are the active sites of the ancestral and modern LDHs ([Figure 7D](#fig7){ref-type="fig"}) and the AncMDH2-INS intermediate ([Figure 7F](#fig7){ref-type="fig"}). In fact, the active sites of the MDHs and the LDHs are also identical in sequence except for the 102 position, and they are otherwise highly structurally similar. Therefore, residues remote from the active sites necessarily affect the substrate specificity of the enzymes.

In principle, these long-range epistatic residue interactions could differentially modify the structure of the active site. Certain residues found in the ancestral MDH, but not in the modern MDH, could position the active site residues so that they allowed the insertion to confer pyruvate activity. In this scenario the active site residues of the ancestral and modern MDHs would be identical, but their conformations would differ due to interactions with residues in other parts of the protein. However, the crystal structures reveal ancestral, intermediate, and modern active sites that are nearly indistinguishable, suggesting that epistasis has modified the protein dynamics or shifted the energy landscape, effects that are largely invisible to static crystal structures.

Epistasis prevents mechanistic convergence in the LDH/MDH superfamily {#s3-5}
---------------------------------------------------------------------

Interestingly, *Bacillus subtilis* (*Bs*) LDH reverts to an MDH with only a single mutation, Gln102Arg, indicating a lack of complicating epistatic effects ([@bib80]). The kinetics of wild-type *Bs*LDH with pyruvate are comparable to those for the Gln102Arg mutant with oxaloacetate (e.g., *Bs*LDH has a k~cat~/K~M~ for pyruvate of 4.2 × 10^6^ M^−1^ s^−1^, and the *Bs*LDH-Q102R mutant has the same k~cat~/K~M~ for oxaloacetate). However, *Bs*LDH likely is an exception in the LDH/MDH superfamily, since the reverse mutation (Arg102Gln) fails to switch specificity in MDHs from two other species ([@bib56]; [@bib14]). In *Haloarcula marismortui* (*Hm*) MDH, the Arg102Gln mutation switches specificity, but the mutant\'s k~cat~/K~M~ for pyruvate is 200-fold less than the wild-type\'s k~cat~/K~M~ for oxaloacetate. The Arg102Gln mutation in *Escherichia coli* (*Ec*) MDH is even less effective, as it converts a highly active MDH to an enzyme with low activity on both substrates (10,000-fold lower k~cat~/K~M~). Hence, the strong epistasis observed in apicomplexan LDH and MDHs is likely a general phenomenon within the superfamily.

LDH evolved convergently from MDH four separate times in the superfamily, but did the activity evolve by the same mechanism each time? Each event has resulted in a different change at the specificity residue (position 102) within the catalytic loop. However, the epistatic effects seen in the apicomplexan, *H. marismortui,* and *E. coli* dehydrogenases indicate that in general position 102 is not solely responsible for the transition from MDH to LDH. In order for the historical LDH mutations to confer pyruvate specificity, additional residues must be present to provide a permissive background ([Figure 8](#fig8){ref-type="fig"}). Due to the presence of different sets of permissive mutations, LDH activity has evolved from an MDH under epistatic constraints by a different mechanism four separate times.

Large effect, gain-of-function mutation {#s3-6}
---------------------------------------

The evolution of AncLDH from AncMDH2 involves a shift in substrate specificity by 12 orders-of-magnitude. Through the characterization of possible evolutionary intermediates, we have found that just two mutations are responsible for the great majority of this switch: the six-residue insertion and the Arg102Lys point mutation. Mutagenesis within the insertion indicates that only a single position, Trp107f, contributes strongly to pyruvate activity and specificity. Both the insertion and Arg102Lys have a large effect on preference for pyruvate vs oxaloacetate, although by differentially affecting activity towards each substrate. Incorporating the six-residue insertion into AncMDH2\'s substrate loop results in a 12,000-fold gain in pyruvate activity with little effect on oxaloacetate activity ([Figure 6](#fig6){ref-type="fig"}). Conversely, mutating Arg102 to Lys reduces oxaloacetate activity by more than 2500-fold, with minimal effect on pyruvate activity ([Figure 6](#fig6){ref-type="fig"}).

The apicomplexan LDH six-residue insertion is an exceptionally large gain-of-function mutation: it enhances pyruvate activity by more than four orders of magnitude while barely affecting oxaloacetate activity. In contrast, other well-studied mutations of large effect are often predominantly deleterious towards one function while modestly enhancing another. The textbook example of a gain-of-function mutation is Gln102Arg in *Bs*LDH, which causes a 10^7^-fold change in the enzyme\'s specificity ([@bib80]). The Gln102Arg mutation reduces pyruvate activity by more than 8000-fold, while enhancing activity towards oxaloacetate by only 1000-fold. Another example is given by *E. coli* isocitrate dehydrogenase (IDH), where seven mutations are necessary to switch the cofactor specificity from a 7000-fold preference for NADP to a 200-fold preference for NAD ([@bib17]). Within this set of mutations, two reduce specificity for NADP by 6000-fold, whereas the rest enhance NAD usage 200-fold. Thus, while mutations can have both deleterious and beneficial effects on different functions, the deleterious effects typically appear greater than enhancement.

In previous ancestral sequence reconstruction studies, mutations of large effect are in fact usually loss-of-function rather than gain-of-function (e.g., RNaseA \[[@bib46]\], chymase \[[@bib83]\], and glucocorticoid receptors \[[@bib7]; [@bib58]; [@bib12], [@bib13]\]). In these studies, the modern proteins are generally specific for one substrate, whereas the ancestral proteins are promiscuous. Furthermore, the activity of the ancestral protein is comparable to the modern descendants. Therefore, these proteins specialized by accumulating deleterious mutations, with the modern, specialized activity being the 'last function standing'. For example, the ancestral glucocorticoid receptor binds three steroid hormones tightly (EC~50~ \<10 nM for aldosterone, deoxycorticosterone, and cortisol), while the modern receptors bind only cortisol (EC~50~ ∼ 100 nM) ([@bib58]). Seven historical mutations produced the modern cortisol preference by completely eliminating aldosterone and deoxycorticosterone sensitivity yet reducing cortisol sensitivity only 50-fold. In other ancestral reconstruction studies, function-enhancing mutations have relatively minor effects, all less than a 50-fold gain in k~cat~/K~M~ ([@bib87]; [@bib75]; [@bib63]).

During the evolution of the malate and lactate dehydrogenase superfamily, pyruvate activity has converged multiple times despite strong constraints due to epistasis. While epistasis may constrain evolutionary options locally, there are nevertheless multiple ways to 'skin the cat' in more distant regions of protein sequence space. The apicomplexan enzymes provide a clear example of neofunctionalization in protein evolution and thereby validate the plausibility of this particular mechanism of gene duplication. Specialization mechanisms may be more common, but the evolution of novel function does not require a promiscuous genesis.

Accession numbers {#s3-7}
-----------------

The PDB accession codes for the coordinates and structure factor files reported in this paper are 4PLC, 4PLF, 4PLG, 4PLH, 4PLT, 4PLV, 4PLW, 4PLY, and 4PLZ.

Materials and methods {#s4}
=====================

Modern sequences {#s4-1}
----------------

Protein sequences used in the phylogenetic analyses were identified through searches of the non-redundant database ([@bib60]) with the BLASTP algorithm ([@bib2]) using selected query sequences. All sequences from these searches that returned BLASTP E-values \<10^−7^ were downloaded from NCBI ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)). Multiple complete apicomplexan genomes ([@bib44]; [@bib36]; [@bib4]) were also searched for LDH and MDH homologs in order to fill out the apicomplexan portion of the tree (using a more lenient significance cutoff of E-values \<10^−4^). Redundant sequences, synthetic constructs, and sequences from PDB files were removed. To reduce phylogenetic complexity, sequences were curated based on character length and pairwise sequence identity within each dataset (as described below).

The dataset used for the construction of the non-redundant phylogeny ([Figure 3A](#fig3){ref-type="fig"}) was generated using four query sequences, UniProt IDs ([@bib23]): MDHC_HUMAN, LDH_THEP1, MDHP_YEAST, and LDH6A_HUMAN. Multiple sequences were necessary to generate full coverage, due to the low sequence identity across the superfamily, which can be less than 20% between members. Sequences were removed if their character length was less than 280 or greater than 340. Limits were chosen to remove truncated/partial sequences and those featuring large insertions or terminal extensions. Sequences greater than 97% identical, determined by pairwise alignment within the dataset, were also removed. This level of identity provides a high level of detail within the tree while accelerating computational time by removing redundant taxa. The final dataset contains 1844 taxa.

Residue numbering in the text is based on the dogfish LDH convention ([@bib32]) for consistency with previous work.

Primary phylogeny construction {#s4-2}
------------------------------

A multiple sequence alignment of this dataset was generated using the program MUSCLE ([@bib30]). A maximum likelihood (ML) phylogenetic tree was inferred with PhyML 3.0 ([@bib40]) using the LG substitution matrix ([@bib52]) and estimating the gamma parameter (12 categories) and empirical amino acid frequencies. The starting tree was generated by Neighbor-Joining (BIONJ) and searched by Nearest Neighbor Interchange (NNI); tree topology, branch lengths, and rate parameters were optimized. Branch supports were estimated with the approximate likelihood ratio test (aLRT), as implemented in PhyML, represented as either the raw aLRT statistic (roughly \>8 is considered highly significant) or the confidence level that the clade is correct ([@bib3]).

Phylogeny rooting {#s4-3}
-----------------

The outgroup for rooting the L/MDH phylogeny was identified through a profile analysis of the Rossmann fold ([@bib61]), based on a method used for OB folds and SH3 domains ([@bib72]). All structurally characterized Rossmann folds with 40% or less sequence identity were identified from ASTRAL SCOP 1.73 protein domain sequence database ([@bib15]). Each of the 193 domains identified was searched against the SwissProt database ([@bib6]) using BLASTP. A multiple sequence alignment for each query and SwissProt sequences with BLASTP E-values \<10^−10^ was created using MUSCLE. Each alignment was cropped to the limits of the original query. COMPASS ([@bib66]) was then used to generate an all-against-all scoring matrix for the 193 multiple sequence alignments. The E-values generated by COMPASS were converted to evolutionary distances as described in [@bib72]. A weighted least-squares phylogenetic analysis of the distance matrix was performed using PAUP ([@bib70]). First order taxon jackknifing ([@bib51]; [@bib68]) was used to determine the robustness of tree topology, with a consensus tree calculated from all analyses.

Rossmann fold domains from α- and β-glucosidases and aspartate dehydrogenases (AspDH) were identified from the profile--profile analysis as grouping with the Rossmann fold domain from L/MDHs. An L/MDH dataset was constructed for use with the outgroup to create a rooted phylogeny. This dataset was generated by querying four sequences, UniProt IDs: MDHC_HUMAN, LDH_THEP1, MDHP_YEAST, and LDH6A_HUMAN, against the SwissProt database using BLASTP. All sequences from these searches that returned BLASTP E-values \<10^−7^ were downloaded from NCBI ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)). Redundant sequences, synthetic constructs, and sequences from PDB files were removed. Also, four taxa identified as ubiquitin-conjugating enzymes were removed due to sequence length. This SwissProt L/MDH dataset contained 595 taxa.

An outgroup dataset was constructed by querying three sequences, UniProt IDs: LICH_BACSU, AGAL_THEMA, and ASPD_THEMA, against the SwissProt database using BLASTP. All sequences from these searches that returned BLASTP E-values \<10^−7^ were downloaded from NCBI ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov/)). Redundant sequences, synthetic constructs, and sequences from PDB files were removed. The outgroup dataset contained 62 taxa. The SwissProt LDH, MDH, AspDH, and glucosidase datasets were combined and a multiple sequence alignment was generated using the program MUSCLE. The C-terminal domain of the glucosidases and AspDHs were removed from the MUSCLE alignment. A ML phylogenetic tree was inferred from the alignment with PhyML using the LG substitution matrix ([@bib78]) with the gamma parameter estimated over 10 categories, no invariant sites, and estimating empirical amino acid frequencies. The initial tree was obtained by BIONJ and searched by NNI; tree topology, branch lengths, and rate parameters were optimized. Robustness of root positioning was evaluated with two truncated alignments, one with the LDH and 'LDH-like' MDH sequences removed and the other with the cytosolic and mitochondrial MDH sequences removed. Truncated alignments were input to PhyML for phylogenetic analysis using the parameters described above.

Alternative phylogeny construction {#s4-4}
----------------------------------

The dataset for the alternative phylogeny (used in reconstructing alternative ancestors) is smaller and focused on apicomplexan taxa. It was generated by BLASTP searches with four query sequences, UniProt IDs: MDHC_PIG, Q76NM3_PLAF7, C6KT25_PLAF, and MDH_WOLPM for full coverage of the superfamily. Sequences were removed if their length was less than 290 or greater than 340. The dataset was culled to 60% identity, but the apicomplexan clade was filled back to 97% identity to gain resolution within the clade of interest. The final dataset contained 277 taxa. A multiple sequence alignment of this dataset was produced using the program MUSCLE. The ML tree was inferred with PhyML 3.0 using the LG substitution matrix and estimating the gamma parameter (12 categories) and empirical amino acid frequencies. The starting tree was generated by Neighbor-Joining (BIONJ) and searched by Nearest Neighbor Interchange (NNI); tree topology, branch lengths, and rate parameters were optimized.

Ancestral sequence reconstruction {#s4-5}
---------------------------------

Sequences at internal nodes in phylogenies were inferred using the *codeml* program from the PAML software package ([@bib86]). Posterior amino acid probabilities at each site were calculated using the LG substitution matrix, given the ML tree generated by PhyML. The initial ancestral reconstruction assumed the background amino acid frequencies implicit in the LG matrix, while the alternative reconstruction estimated background frequencies from the sequence alignment of the alternative dataset. N-/C-termini of ancestral sequences were modified manually to match those of the closest modern sequence (determined by branch length).

Plasmid construction and mutation {#s4-6}
---------------------------------

*Escherichia coli* codon-optimized coding sequences were constructed for the *Plasmodium falciparum* MDH (gi\#: 86171227), *Cryptosporidium parvum* MDH (gi\#: 32765705), *Toxoplasma gondii* LDH1 (gi\#: 237837615), *Toxoplasma gondii* LDH2 (gi\#: 2497625), *Rickettsia bellii* MDH (gi\#: 91205459), and ancestrally inferred protein sequences. These coding sequences were synthesized and subcloned into pET-24a, bypassing the N-terminal T7-tag but using the C-terminal 6xHis-tag. *Pf*LDH (gi\#: 124513266) with six His residues added to the C-terminus was synthesized and subcloned into pET-11b. All gene synthesis and subcloning was performed by Genscript (Piscataway, NJ). All point mutations were made using the QuikChange Lightning kit from Agilent (Santa Clara, CA) and synthesized primers from IDT (Coralville, IA).

Protein expression and purification {#s4-7}
-----------------------------------

Plasmids were transformed in BL21 DE3 (pLysS) *E. coli* cells (Invitrogen, Grand Island, NY) for expression. Cells were grown at 37°C with 225 rpm agitation in 2xYT media supplemented with 30 mM potassium phosphate, pH 7.8 and 0.1% (wt/vol) glucose. Once cultures reached an OD~600~ between 0.5--0.8, cells were induced with 0.5 mM IPTG for 4 hr. Cells were collected by centrifugation at 10,000*×g* for 15 min and stored at −80°C.

Cell pellets were thawed on ice, releasing lysozyme produced by the pLysS plasmid from within the cells, and resuspended in 15 ml lysis buffer (50 mM NaH~2~PO~4~, pH 8.0, 300 mM NaCl, 10 mM Imidazole) with 375 units of Pierce Universal Nuclease (Thermo Scientific, Rockford, IL) per 1.5 l of culture. Once homogeneously resuspended, lysate was sonicated on ice at 35% amplitude (30 s ON, 20 s OFF, 2 min total). Insoluble cell debris was separated by centrifugation at 18,000*×g* for 20 min.

Proteins were purified by nickel affinity chromatography. Clarified lysate was applied to a 5 ml HisTrap FF column (GE Healthcare, Piscataway, NJ) and eluted via an imidazole gradient from 10 mM to 500 mM on an AKTA Prime (GE Healthcare, Piscataway, NJ). Fractions were analyzed by SDS-PAGE, pooled, and concentrated using Amicon Ultracel-10 K centrifugal filters (Millipore, Billerica, MA). Finally, proteins were desalted into 50 mM Tris, pH 7.4, 100 mM NaCl, 0.1 mM EDTA and 0.01% azide by either PD10 column (GE Healthcare, Piscataway, NJ) or gel filtration over a HiPrep 16/60 Sephacryl S-200 HR column (GE Healthcare, Piscataway, NJ) on an AKTA Purifier (GE Healthcare, Piscataway, NJ). Enzyme concentrations were determined by absorbance at 280 nm, using extinction coefficients and molecular weights calculated by ExPASy\'s ProtParam tool (<http://web.expasy.org/protparam/>).

Steady-state kinetic assays {#s4-8}
---------------------------

Enzymatic reduction of pyruvate and oxaloacetate was monitored at 25°C by following the decrease in absorbance at 340 nm due to NADH oxidation on a Cary 100 Bio (Agilent, Santa Clara, CA) in 50 mM Tris, pH 7.5, 50 mM KCl. All substrates were purchased from Sigma-Aldrich (St. Louis, MO). NADH concentration was held constant at 200 μM while pyruvate/oxaloacetate concentrations were titrated. Enzyme concentrations ranged from 0.28 nM to 2.8 μM, depending on enzyme activity for a particular substrate. All experiments used 1-cm path-length quartz cuvettes with 500 μl final volume of reaction mixture.

Kinetic parameters were estimated by chi-squared fitting to either the Michaelis-Menton equation (v/\[E\]~t~ = k~cat~ \[S\]/(K~M~ + \[S\])) or a substrate inhibition equation (v/\[E\]~t~ = k~cat~ \[S\]/(K~M~ + \[S\] + \[S\]^2^/K~i~)) using the KaleidaGraph software. Three datasets were fit using a modified substrate inhibition equation with K~M~ = K~i~ for identifiability and to prevent the K~i~ being less than K~M~. These datasets were: AncMDH2-INS-59Mut oxaloacetate and AncMDH2-R102Q for both oxaloacetate and pyruvate. Kinetic constants k~cat~, K~M~, and k~cat~/K~M~ are consistently reported in units of s^−1^, M, and s^-1^M^−1^, respectively.

Aqueous oxaloacetate spontaneously decarboxylates to pyruvate at 25°C and neutral pH at a rate of ∼3 × 10^−5^ s^−1^ (approximately 10% per hr) ([@bib82]). As a result, oxaloacetate preparations contain appreciable pyruvate contamination (approximately 1--3% from Sigma-Aldrich, depending on batch) and must be handled with care. All oxaloacetate stock solutions were made fresh before each assay and kept on ice to keep decarboxylation to a minimum. For enzymes with low pyruvate activity, the oxaloacetate decarboxylation has a negligible affect on measured rates. However, enzymes with appreciable pyruvate activity can display an apparent, artifactual oxaloacetate activity that is due to pyruvate contamination ([@bib59]; [@bib80]; [@bib67]). In this work, seven such proteins are *Pf*LDH, *Pf*LDH-K102R, *Tg*LDH1, *Tg*LDH2, AncLDH, AncLDH\*, and AncMDH2-INS-R102K. For these proteins, oxaloacetate activity was assayed at high enzyme concentration (600 nM--1 μM), resulting in a biphasic ΔA~340~ trace with an initial burst in which pyruvate is rapidly consumed followed by a slower linear phase representing oxaloacetate reduction. The post-burst (slow) phase of the ΔA~340~ trace was used to quantify the oxaloacetate catalytic rate ([@bib59]; [@bib80]). This procedure controls for the standing pyruvate contamination but does not account for the relatively slow spontaneous decarboxylation during the assay. Hence, the oxaloacetate k~cat~/K~m~ values for the seven enzymes with high pyruvate activity should be considered upper limits on the true oxaloacetate activity. The low or negligible oxaloacetate activities of these seven enzymes were further confirmed by undetectable malate/NAD^+^ reactions in spectroscopic steady state enzyme assays, and the absence of malate product as determined from 1D proton NMR (3 μM enzyme, 5 mM oxaloacetate, 5 mM NADH in NaCl/P~i~/D~2~O pH 7.5 over four hour reaction) ([@bib67]).

Protein crystallization {#s4-9}
-----------------------

Crystallization trials were conducted by hanging-drop vapor-diffusion at room temperature using Crystal Screen and Crystal Screen 2 from Hampton Research (Aliso Viejo, CA). Drops consisting of 2 μl reservoir solution and 2 μl protein stock were equilibrated against 1 ml of reservoir solution. Crystals of the ancestral proteins were identified from condition \#43 of Crystal Screen (30% (wt/vol) polyethylene glycol 1500) and further refined by adding 0.1 M sodium HEPES.

Crystals of the ternary complexes were grown at room temperature by hanging-drop vapor-diffusion with 4 μl drops of 1:1 precipitating buffer:protein. AncMDH2 (25 mg/ml) was co-crystallized with 2 mM oxamate/NADH in 35% (wt/vol) PEG-1500, 0.1 M sodium HEPES, pH 7.5 and with 2 mM L-lactate/NADH in 30% (wt/vol) PEG-1500, 0.1 M sodium HEPES, pH 7.3. AncMDH2-INS (18 mg/ml) was co-crystallized with 1 mM oxamate/NADH and 1 mM L-lactate/NADH in 25% (wt/vol) PEG-1500, 0.1 M sodium HEPES, pH 8.1. AncLDH\* (20 mg/ml) was co-crystallized with 2 mM oxamate/NADH and 2 mM L-lactate/NADH in 20% (wt/vol) PEG-1500, 0.1 M sodium HEPES, pH 7.5. *Pf* LDH_W107fA (20 mg/ml) was co-crystallized with 1.2 mM oxamate/2 mM NADH in 22% (wt/vol) PEG-1000.

All crystals were cryoprotected with a 30% (wt/vol) dextrose solution (15 mg dextrose dissolved in 50 μl reservoir solution). Crystals were harvested from the drop, soaked in 15% (wt/vol) dextrose solution for 3 min, transferred to the 30% solution, and flash-frozen immediately in liquid N~2~.

Structure determination {#s4-10}
-----------------------

Diffraction datasets were collected at the SIBYLS beamline (12.3.1, Lawrence Berkeley National Laboratory, Berkeley, CA). All datasets were indexed, integrated, and scaled with XDS/XSCALE ([@bib85]). Datasets included all reflections that were significant according to the CC(1/2) criterion (flagged as '\*' in the XDS output), which typically extended to much weaker data than the conventional 2 sigma cutoff ([@bib47]; [@bib27]). The resolution of the data is defined as the resolution bin where CC(1/2) = 0.5. Structures were solved by molecular replacement using AutoMR in PHENIX ([@bib1]). Homology models for the AncMDH2 and AncLDH\* datasets were generated by the Phyre2 server ([@bib49]). The AncMDH2 homology model was based on the structure for *Cryptosporidium parvum* MDH (2hjr, 62% sequence identity, [@bib74]), while the model for AncLDH\* was based on the *Toxoplasma gondii* LDH1 structure (1pzf, 65% sequence identity, [@bib48]). AncMDH2-INS datasets were solved using the AncMDH2 structure as the model. *Pf* LDH_W107fA dataset was solved using the *P. falciparum* LDH structure (1t2d) structure as a model. All models were improved by rounds of manual building in Coot ([@bib31]) and refinement by phenix.refine in PHENIX. Model quality of all structures was validated with MolProbity ([@bib25]; [@bib18]) in PHENIX. All structural alignments were generated using THESEUS ([@bib73]). Structure images were rendered with PyMOL.

In all structure models, the enzyme is generally found in either of two states, the loop-open state or the loop-closed state, and often both states are observed in different monomers (chains) in the asymmetric unit. Loop-open states are generally more disordered (with higher B-factors) and sometimes the chain could not be traced for the loop. In loop-open states the substrate typically also has weak electron density and cannot be fit reliably. In loop-closed states the substrate generally has strong electron density, but complications arose for proteins co-crystallized with lactate and malate.

NADH will eventually oxidize to NAD+ spontaneously in the crystals and during data collection due to oxidative radiation damage. Malate can also oxidize to oxaloacetate in the crystals, and oxaloacetate is expected to spontaneously decarboxylate to pyruvate relatively quickly (over the multi-week time frame of crystallization). Additionally, pyruvate spontaneously reacts with NAD+ to form a covalent pyruvate-NAD adduct ([@bib79]). Although we added NADH to the crystallization mixture, we cannot reliably determine whether NADH, NAD+, or a mixture of the two is found in the crystals, and we have variable evidence for the pyruvate-NAD adduct. In both of the structures crystallized with malate (4plc and 4ply), the substrate electron density and loop conformation indicated that the malate had converted to pyruvate and/or lactate. Therefore, for the enzymes crystallized with lactate and malate, the fine details of substrate conformation and identity in the models should be viewed with skepticism, as we are fairly confident we have an unresolvable mixture of pyruvate, lactate, and pyruvate-NAD adduct in the active site, all of which will produce similar electron density. These concerns with substrate do not apply to the oxamate models (although the uncertainty in cofactor state still remains). Finally, in the 4plw model (AncMDH2 crystallized with lactate), clear phosphates were seen in the active site instead of lactate, presumably carried through from the initial purification step.
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**Sequences, alignments, and trees**. Alignments and tree files for both the original ([Figure 3](#fig3){ref-type="fig"}) and the alternative phylogeny. Alignment for [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}. Ancestral FASTA files and posterior probabilities for each ancestral sequence (parsed in [Figure 6---figure supplements 1--6](#fig6s1 fig6s2 fig6s3 fig6s4 fig6s5 fig6s6){ref-type="fig"}).
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**Molecular weights and extinction coefficients**. ExPASy calculated molecular weights and extinction coefficients for all proteins used within this study.

**DOI:** [http://dx.doi.org/10.7554/eLife.02304.034](10.7554/eLife.02304.034)

Major dataset
-------------

The following datasets were generated:

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan lactate dehydrogenase with malate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plc>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan lactate dehydrogenase with lactate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plf>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan lactate dehydrogenase with oxamate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plg>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan malate dehydrogenase with oxalate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plh>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan malate dehydrogenase with oxamate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plt>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan malate dehydrogenase with lactate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plv>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan malate dehydrogenase with lactate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plw>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of ancestral apicomplexan malate dehydrogenase with malate,<http://www.pdb.org/pdb/explore/explore.do?structureId=4ply>,Publicly available at RCSB Protein Data Bank.

BoucherJI, JacobowitzJR, BeckettBC, ClassenS, TheobaldDL, 2014,Crystal structure of Plasmodium falciparum lactate dehydrogenase mutant W107fA,<http://www.pdb.org/pdb/explore/explore.do?structureId=4plz>,Publicly available at RCSB Protein Data Bank.

The following previously published datasets were used:

VedadiM, LewJ, ArtzJ, AmaniM, ZhaoY, DongA, WasneyGA, GaoM, HillsT, BrokxS, QiuW, SharmaS, DiassitiA, AlamZ, MeloneM, MulichakA, WernimontA, BrayJ, LoppnauP, PlotnikovaO, NewberryK, SundararajanE, HoustonS, WalkerJ, TempelW, BochkarevA, KozieradzkiI, EdwardsA, ArrowsmithC, RoosD, KainK, HuiR, 2007,Crystal Structure of Cryptosporidium parvum malate dehydrogenase,<http://www.pdb.org/pdb/explore/explore.do?structureId=2hjr>,Publicly available at RCSB Protein Data Bank.

KavanaghKL, EllingRA, WilsonDK, 2004,T.gondii LDH1 ternary complex with APAD+ and oxalate<http://www.pdb.org/pdb/explore/explore.do?structureId=1pzf>Publicly available at RCSB Protein Data Bank.

CameronA, ReadJ, TranterR, WinterVJ, SessionsRB, BradyRL, VivasL, EastonA, KendrickH, CroftSL, BarrosD, LavanderaJL, MartinJJ, RiscoF, Garcia-OchoaS, GamoFJ, SanzL, LeonL, RuizJR, GabarroR, MalloA, De Las HerasFG, 2004,Plasmodium falciparum lactate dehydrogenase complexed with NAD+ and oxalate,<http://www.pdb.org/pdb/explore/explore.do?structureId=1t2d>,Publicly available at RCSB Protein Data Bank.

WinterVJ, CameronA, TranterR, SessionsRB, BradyRL, 2003,Lactate dehydrogenase from Plasmodium berghei,<http://www.pdb.org/pdb/explore/explore.do?structureId=1oc4>,Publicly available at RCSB Protein Data Bank.

RotheryEL, MowatCG, MilesCS, WalkinshawMD, ReidGA, ChapmanSK, 2003,H61M mutant of flavocytochrome c3,<http://www.pdb.org/pdb/explore/explore.do?structureId=1p2h>,Publicly available at RCSB Protein Data Bank.

KavanaghKL, WilsonDK, ,T. gondii bradyzoite-specific LDH (LDH2) in complex with NAD and oxalate,<http://www.pdb.org/pdb/explore/explore.do?structureId=1sow>,Publicly available at RCSB Protein Data Bank.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for sending your work entitled "An atomic-resolution view of neofunctionalization in the evolution of apicomplexan lactate dehydrogenases" for consideration at *eLife.* Your article has been favorably evaluated by a Senior editor, a Reviewing editor, and 2 reviewers.

The Reviewing editor and the reviewers discussed their comments before we reached this decision. If you have any questions about prioritizing changes in response to these comments, please do not hesitate to contact us for advice.

Please examine these comments with great care. They come from two preeminent experts and both reviewers will need to be satisfied with your revised manuscript.

Reviewer \#1:

Boucher et al explore the genesis and evolution of apicomplexan lactate dehydrogenase (LDH) by gene duplication of a malate dehydrogenase (MDH) followed by a shift in substrate specificity. They combine phylogeny, sequence analysis and ancestral reconstruction with protein crystallography and enzymatic assays to determine sequences underlying substrate specificity and possible evolutionary paths for the shift in function. This multi-functional approach provides new insights into the shift of enzyme function in this case, and may be relevant to the evolution of other enzymes.

The omission of the underlying data for the sequence analysis -- protein sequences, alignments, trees, and ancestral sequences -- severely detract from the paper, both as an overall advance in understanding of this enzyme evolution and for the general method, as well as for my ability to review it. I strongly urge that these data be provided in a useful manner (i.e. machine-readable text files, not pdfs).

The paper is well written from an English language and grammatical point of view, but I found the flow of the arguments to be difficult to follow, frequently overstated, and not always cohesive.

MDH/LDH Phylogeny Analysis:

The breadth of the phylogenetic analysis is not clear. The use of several starting proteins for Blast analysis, and a tight cutoff rather than psi-blast or HMMs, cast some doubt on how comprehensive the survey of MDH/LDH homologs is.

The phylogenetic analysis would greatly benefit from an explicit discussion of the species distributions. Are the mitochondrial and cytosolic MDHs unique to and universal across free-living eukaryotes? Where do bacterial and archaeal MDHs fall? Are the LDHs also found in all free-living eukaryotes? Why was LDH re-invented in apicomplexans and Trichomonas - do they also have a canonical LDH, or as obligate parasites, did their ancestors lose it? Can glycolysis still proceed and lactate be excreted in the absence of LDH? The answers to these questions are important in providing an evolutionary and functional context for the evolution of these new LDH genes and the possible functionality of ancestral enzymes of relaxed specificity.

The text states that "α/β- glucosidases and aspartate dehydrogenases as outgroups", but only a single α-glucosidase is shown in the figure. According to SCOP, the MDH/LDH and α/β- glucosidases share a superfamily, but the aspDH are in a separate superfamily. These discrepancies should be resolved.

The only support for the hypothesis that LDHs derived from "LDH-like MDHs" is the statement in the figure legend that this branch has an aLRT support of 42. Please explain this measurement and why it supports the claim of 4 inventions of LDH from MDH, and document the use of the aLRT in the Methods. Certainly these LDHs cannot be said to be "deep within MDH clades", unlike the other cases. Likewise, the claim that the rooting of the tree divides it into two major clades is not quantitatively supported.

Sequence Analysis and Ancestral Sequence Reconstruction:

The authors oversimplify the initial comparison of apicomplexan LDH and MDH proteins, focusing on the 5-AA insert (confusingly referred to as a "6-residue loop insertion"), resulting in an awkward backtrack in later sections, where they are forced to consider additional changes between sequences. A more complete analysis of the substantial changes between Apicomplexan MDH and LDH proteins at the beginning would be far more helpful, informative, and clear. This should include mention of position 103, which is within the loop region and is substantially different in LDH (small hydrophobic) from MDH (basic). It is not surprising that an alanine scan would have little effect on this position; a mutation to the \'ancestral\' lysine would be more informative. Since it is adjacent to K102 and of the same charge, it is more likely than not that this change influences either substrate specificity or enzyme activity.

The claim that Trp107f is the "modern apicomplexan specificity residue" is a bit overblown. It is the most important single residue to determine specificity and activity within the context of the insertion and other aspects of apicomplexan LDH, but it is unhelpful to strongly analogize with the traditional specificity residue at \#102. Its molecular mechanism is not described and the uniqueness of its importance is also not resolved. Supplemental [Figure 4B](#fig4){ref-type="fig"} lacks any legend and I find it difficult to interpret.

The epistatic interactions seem to be over-interpreted. For instance, there is a discussion section headed "Convergent evolution of apicomplexan LDH involved long-range epistasis" but this is only inferred from the lack of obvious short-range epistasis, and no mechanistic model is presented for what this epistasis might be. Similarly, the conclusion that epistatic interactions are common simply because residue 102 mutations do not always result in strong substrate switching is not warranted; for epistasis to be shown, an interaction between two mutations must be directly shown.

The claims that: "there are no clear examples of classic neofunctionalization or gain-of-function mutations" and "the apicomplexan enzymes provide the first clear example of neofunctionalization in protein evolution" is unsupported. Cited previous examples include RNaseA, an antifreeze protein in Antarctic zoarcid fish (PMID: 21115821), and retinoic acid receptors (PMID: 16839186). It could also be argued that since the MDH/LDH system simply involves changing substrate specificity, that the change is not particularly \'neo\' but rather a tuning of an existing function.

Reviewer \#2:

In this interesting manuscript, the authors describe a well-supported case of neofunctionalization after gene duplication. The authors chose a unique enzyme that is a malaria drug target and convincingly demonstrate that it gained a new function after originating by gene duplication of an enzyme horizontally transferred from bacteria. Interestingly, this new function is not only essential for these protist parasites, but also has an analogous (independently evolved, convergent) counterpart in other organisms.

I think this might become a textbook example of neofunctionalization, because it is so thoroughly supported by ample evidence, from computation to biochemistry and crystallography. As such, I think it would make the paper more attractive, if some of the material is summarized better. E.g., a summary "graphical abstract" figure that shows the logic of the project, and tells the whole story at a glance might be great to have. Currently, the key important points drown in the minutiae of rationalizations and experimental details. Not that the manuscript is poorly written. I think it is very good, and the subsection title lines are particularly well-crafted. However, some further thinking might be in order to increase the impact of the paper and make it more accessible to a wider audience. Also, it would be great to articulate and summarize explicitly the mechanisms that confer specificity in 3 enzymes: MDH and two convergent LDHs. E.g., "characterized by long-range epistasis, a promiscuous intermediate, and relatively few gain-of-function mutations of large effect" is an excellent summary, but it does not help much in terms of mechanistic understanding. I would love to see (not necessarily in the Abstract) equally crisp mechanistic summary. The beauty of this work is in gaining so many insights into the mechanism, and I think it should be highlighted better.

On a technical side, I am impressed with the crystallography and the role of structures in the project. It should be noted, however, that ancestral reconstruction from highly divergent present-day sequences is a very difficult problem and is prone to many types of errors. The authors should be commended on exploring alternative reconstructions. Also, along the lines that final results justify the means, the authors show that "resurrected" proteins are very specific to their expected substrates. However, I would like to see more discussion and thought devoted to uncertainty with reconstruction, and zooming in the regions and substitutions that confer specificity. I am not suggesting any additional experiments -- what the authors did looks sufficient -- but simply giving a reader better appreciation that ancestral reconstruction is always highly hypothetical and is never truly reliable might be useful. Is it at all conceivable that the ancestral enzyme had broader specificity, but reconstruction methods were overwhelmed by the number of bacterial MDHs or what not? Nature is there to fool you.

10.7554/eLife.02304.036

Author response

Reviewer \#1:

*Boucher et al explore the genesis and evolution of apicomplexan lactate dehydrogenase (LDH) by gene duplication of a malate dehydrogenase (MDH) followed by a shift in substrate specificity. They combine phylogeny, sequence analysis and ancestral reconstruction with protein crystallography and enzymatic assays to determine sequences underlying substrate specificity and possible evolutionary paths for the shift in function. This multi-functional approach provides new insights into the shift of enzyme function in this case, and may be relevant to the evolution of other enzymes*.

*The omission of the underlying data for the sequence analysis -protein sequences, alignments, trees, and ancestral sequences -- severely detract from the paper, both as an overall advance in understanding of this enzyme evolution and for the general method, as well as for my ability to review it. I strongly urge that these data be provided in a useful manner (i.e. machine-readable text files, not pdfs)*.

We agree, apologize for the oversight, and now provide this important additional data and information, including all sequences, alignments, and trees in plain text.

MDH/LDH Phylogeny Analysis:

*The breadth of the phylogenetic analysis is not clear. The use of several starting proteins for Blast analysis, and a tight cutoff rather than psi-blast or HMMs, cast some doubt on how comprehensive the survey of MDH/LDH homologs is*.

We want to emphasize that the purpose of our paper is not to provide a comprehensive phylogenetic analysis of all MDH/LDH homologs, as this has been done previously by others ([@bib55], 2004; [@bib38]; Zhou and Keithly 2002). Our analysis, though much broader than these studies, largely supports the major conclusions from the earlier work. Rather, we focus on the Apicomplexan homologs, esp. the convergent LDHs, which have received less phylogenetic attention.

*The phylogenetic analysis would greatly benefit from an explicit discussion of the species distributions. Are the mitochondrial and cytosolic MDHs unique to and universal across free-living eukaryotes? Where do bacterial and archaeal MDHs fall? Are the LDHs also found in all free-living eukaryotes? Why was LDH re-invented in apicomplexans and Trichomonas -- do they also have a canonical LDH, or as obligate parasites, did their ancestors lose it? Can glycolysis still proceed and lactate be excreted in the absence of LDH? The answers to these questions are important in providing an evolutionary and functional context for the evolution of these new LDH genes and the possible functionality of ancestral enzymes of relaxed specificity*.

We have now added a few sentences addressing each of these questions in the main text ("Results: LDH enzymes have evolved independently at least four times"), including a new supplemental figure highlighting the bacterial, eukaryotic, and archaeal distribution on the global tree ([Figure 3--figure supplement 2](#fig3s2){ref-type="fig"}).

*The text states that "α/β- glucosidases and aspartate dehydrogenases as outgroups", but only a single α-glucosidase is shown in the figure. According to SCOP, the MDH/LDH and α/β- glucosidases share a superfamily, but the aspDH are in a separate superfamily. These discrepancies should be resolved*.

As explained in the Methods, the closest Rossmann folds were used to root the tree, as determined from a profile-based phylogenetic analysis. Apparently, only the Rossmann fold domains of the MDH/LDHs and the aspDHs are homologous.

*The only support for the hypothesis that LDHs derived from "LDH-like MDHs" is the statement in the figure legend that this branch has an aLRT support of 42. Please explain this measurement and why it supports the claim of 4 inventions of LDH from MDH, and document the use of the aLRT in the Methods. Certainly these LDHs cannot be said to be "deep within MDH clades", unlike the other cases. Likewise, the claim that the rooting of the tree divides it into two major clades is not quantitatively supported*.

We have expanded the section on the rooting, and we now also explain the aLRT branch support statistic (developed by Olivier Gascuel and colleagues, and implemented in PhyML), and show the supports on the tree in [Figure 3 -- figure supplement 1](#fig3s1){ref-type="fig"}. Briefly, the aLRT is an approximate log-likelihood ratio statistic, where raw values \> 8 are roughly "statistically significant", representing an e\^8=3000-fold better fit of the tree to the data when the clade is present (in terms of the likelihood). The aLRT can also be used in a traditional significance test to provide a confidence level (between 0 and 1, similar to a probability) for a clade. While the exact ML position of the root is poorly supported, there is very high support for a root position within the MDH portion of the tree, somewhere near the center.

Sequence Analysis and Ancestral Sequence Reconstruction:

*The authors oversimplify the initial comparison of apicomplexan LDH and MDH proteins, focusing on the 5-AA insert (confusingly referred to as a "6-residue loop insertion"), resulting in an awkward backtrack in later sections, where they are forced to consider additional changes between sequences. A more complete analysis of the substantial changes between Apicomplexan MDH and LDH proteins at the beginning would be far more helpful, informative, and clear*.

We have expanded the description of the differences between the modern MDH and LDH proteins.

*This should include mention of position 103, which is within the loop region and is substantially different in LDH (small hydrophobic) from MDH (basic). It is not surprising that an alanine scan would have little effect on this position; a mutation to the \'ancestral\' lysine would be more informative. Since it is adjacent to K102 and of the same charge, it is more likely than not that this change influences either substrate specificity or enzyme activity*.

We originally thought that the 103 position was unlikely to be responsible for differences in activity/specificity between the apicomplexan MDH and LDHs. Our reasoning was based on the following structural evidence. In the crystal structures, the MDH Lys103 points in the opposite direction of Arg102, away from the active site, not contacting the substrate; (the positively charged nitrogens in the two sidechains are over 11 angstroms distant). Similarly, the beta carbon of the LDH 103 residue (Ala,Val,Leu, or Ile) points away from the active site into solution, in the opposite direction of Lys102, at the tip of the insertion in the loop, relatively far from active site and substrate. Nevertheless, data always trumps words, so at the reviewer's suggestion we made the A103K mutation in both the modern *Pf*LDH and in the ancestor. Both mutants are kinetically indistinguishable from WT for both pyruvate and oxaloacetate, confirming our original inclination.

*The claim that Trp107f is the "modern apicomplexan specificity residue" is a bit overblown. It is the most important single residue to determine specificity and activity within the context of the insertion and other aspects of apicomplexan LDH, but it is unhelpful to strongly analogize with the traditional specificity residue at \#102. Its molecular mechanism is not described and the uniqueness of its importance is also not resolved*.

As the reviewer agrees, our data indicates that Trp107f residue is "the most important single residue to determine specificity and activity within the context of the insertion and other aspects of the apicomplexan LDH" -- hence our assertion that Trp107f is the apicomplexan "specificity residue" (a convenient yet simplistic label). Clearly Trp107f is not the only residue important for specificity -- a major point of our paper -- but the same is true of the "traditional" specificity residue at position 102, which is at best necessary but insufficient for determining substrate specificity.

The molecular mechanism by which apicomplexan Trp107f contributes to pyruvate recognition likely involves the hydrophobic Trp sidechain interacting with the hydrophobic pyruvate methyl and the bulky Trp sidechain sterically occluding the methylene carboxylate of oxaloacetate. We have now added a sentence to this effect in the text.

*Supplemental* [*Figure 4B*](#fig4){ref-type="fig"} *lacks any legend and I find it difficult to interpret*.

We now provide a legend for [Figure 4B](#fig4){ref-type="fig"}. The main point is that the W107fA mutant is highly similar to the WT, except for the active site loop which is partially disordered and in the open conformation.

*The epistatic interactions seem to be over-interpreted. For instance, there is a discussion section headed "Convergent evolution of apicomplexan LDH involved long-range epistasis"but this is only inferred from the lack of obvious short-range epistasis, and no mechanistic model is presented for what this epistasis might be*.

Our conclusion of long-range epistasis is not based on negative evidence. Rather, epistasis is defined as a mutation having different effects depending on the identity of residues at other sites. Our data provide clear evidence of this; both the R102K mutation and the loop insertion have differing kinetic effects when introduced in the modern vs ancestral proteins. The residues that comprise the active sites of the modern and ancestral proteins are identical; the residue differences are found only at sites removed from the active site. Hence, the epistasis we observe is necessarily long-range. Elucidating the precise mechanism of this long-range epistasis will not be trivial, but it is currently one of our major ongoing projects. We suspect that the mechanism will come down to shifting energy landscapes (a type of protein dynamics).

*Similarly, the conclusion that epistatic interactions are common simply because residue 102 mutations do not always result in strong substrate switching is not warranted; for epistasis to be shown, an interaction between two mutations must be directly shown*.

Residue 102 mutations frequently result in different levels of substrate specificity, depending on which protein they are made in. This is direct, *prima facie* evidence of epistasis, by definition. Epistatic interactions are not restricted to two sites, but can exist between different sets of sites.

*The claims that: "there are no clear examples of classic neofunctionalization or gain-of-function mutations" and "the apicomplexan enzymes provide the first clear example of neofunctionalization in protein evolution" is unsupported. Cited previous examples include RNaseA, an antifreeze protein in Antarctic zoarcid fish (PMID: 21115821), and retinoic acid receptors (PMID: 16839186). It could also be argued that since the MDH/LDH system simply involves changing substrate specificity, that the change is not particularly \'neo\' but rather a tuning of an existing function*.

We agree with the reviewer that there are other potential examples of neo-functionalization, and that what counts as a new function is largely a matter of degree. We have therefore changed "the first clear example" to "a clear example".

Reviewer \#2:

*In this interesting manuscript, the authors describe a well-supported case of neofunctionalization after gene duplication. The authors chose a unique enzyme that is a malaria drug target and convincingly demonstrate that it gained a new function after originating by gene duplication of an enzyme horizontally transferred from bacteria. Interestingly, this new function is not only essential for these protist parasites, but also has an analogous (independently evolved, convergent) counterpart in other organisms*.

*I think this might become a textbook example of neofunctionalization, because it is so thoroughly supported by ample evidence, from computation to biochemistry and crystallography. As such, I think it would make the paper more attractive, if some of the material is summarized better. E.g. a summary "graphical abstract" figure that shows the logic of the project, and tells the whole story at a glance might be great to have. Currently, the key important points drown in the minutiae of rationalizations and experimental details. Not that the manuscript is poorly written. I think it is very good, and the subsection title lines are particularly well-crafted. However, some further thinking might be in order to increase the impact of the paper and make it more accessible to a wider audience*.

We have made a new graphic that succinctly summarizes the mutation experiments. We hope that [Figure 5](#fig5){ref-type="fig"} already provides a good graphical summary of the phylogenetic and activity data.

*Also, it would be great to articulate and summarize explicitly the mechanisms that confer specificity in 3 enzymes: MDH and two convergent LDHs. E.g., "characterized by long-range epistasis, a promiscuous intermediate, and relatively few gain-of-function mutations of large effect" is an excellent summary, but it does not help much in terms of mechanistic understanding. I would love to see (not necessarily in the Abstract) equally crisp mechanistic summary. The beauty of this work is in gaining so many insights into the mechanism, and I think it should be highlighted better*.

We have now added a couple sentences regarding the mechanism to the Abstract, and we have also added a new section in the Discussion that goes into this in detail ("An alternate mechanism of specificity in the convergent apicomplexan LDH").

*On a technical side, I am impressed with the crystallography and the role of structures in the project. It should be noted, however, that ancestral reconstruction from highly divergent present-day sequences is a very difficult problem and is prone to many types of errors. The authors should be commended on exploring alternative reconstructions. Also, along the lines that final results justify the means, the authors show that "resurrected" proteins are very specific to their expected substrates. However, I would like to see more discussion and thought devoted to uncertainty with reconstruction, and zooming in the regions and substitutions that confer specificity. I am not suggesting any additional experiments -- what the authors did looks sufficient -- but simply giving a reader better appreciation that ancestral reconstruction is always highly hypothetical and is never truly reliable might be useful. Is it at all conceivable that the ancestral enzyme had broader specificity, but reconstruction methods were overwhelmed by the number of bacterial MDHs or what not? Nature is there to fool you*.

We have expanded the section on the alternate reconstructions.
